 FREMONT, Calif., Oct. 04, 2021 GLOBE NEWSWIRE -- Zosano Pharma Corporation NASDAQ:ZSAN, a clinical-stage biopharmaceutical company, today announced the company has been granted a Type C written response only meeting with the U.S. Food and Drug Administration FDA regarding the resubmission of the M207 zolmitriptan transdermal microneedle system 505b2 New Drug Application NDA following receipt of preliminary top-line results from the pharmacokinetic PK study. 